Adial Pharmaceuticals (NASDAQ: ADIL) — Perfil da empresa, notícias e dados financeiros
Adial Pharmaceuticals (NASDAQ:ADIL) develops innovative treatments targeting addiction and substance use disorders with a genetic approach.
Adial Pharmaceuticals
Adial Pharmaceuticals (NASDAQ:ADIL) focuses on developing treatments for addiction and disorders related to substance use. Their flagship project targets the genetic predisposition of individuals with alcohol use disorder, aiming to introduce a genetic-driven approach to treatment that could revolutionize how addictions are managed. Besides alcohol addiction, they are extending their research and development efforts to address opioid withdrawal symptoms, marking a significant stride towards tackling the opioid crisis. With a mission rooted in innovation and patient care, Adial Pharmaceuticals strives to make substantial impacts on public health by addressing some of the most challenging substance use issues facing society today.
Resumo
Operações
Produtos e/ou serviços de Adial Pharmaceuticals
- AD04 for alcohol use disorder, leveraging genetic targeting for higher treatment efficacy.
- A companion diagnostic genetic test to identify patients likely to benefit from AD04.
- AD04 development for opioid use disorder, applying its genetic targeting approach.
- Expansion into precision medicine, focusing on genetic predispositions for effective treatment strategies.
- Research on potential treatments for other substance use disorders, using the genetic targeting framework.
- Strategic partnerships for the distribution and commercialization of its diagnostic and pharmaceutical products.
equipe executiva do Adial Pharmaceuticals
- Cary John ClaiborneCEO, President & Director
- Vinay ShahCFO & Treasurer
- Andrew TaubmanVice President of Corporate Development
- Matthew DavidsonChief Development Officer & Director
- Julie SaikiExecutive Vice President of Strategy
- Abel SvitavskyController
Últimas notícias sobre a Adial Pharmaceuticals
Principais indicadores financeiros
Resultados divulgados pela Adial Pharmaceuticals, em USD.
- Cap. de mercado
- 13,3 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -27.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -7,8 mi | -8 mi | |
| 0 | -8,3 mi | -13,2 mi | |
| 0 | -6,9 mi | -7 mi | |
| 0 | -10,9 mi | -12,7 mi |